VYNE THERAPEUTICS INC

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: -

Employees: -

Market Cap: $26.5M

Website

Clinical Trials

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Vehicle Foam
Drug: FMX-101, 4% minocycline foam

First Posted Date: 2016-06-28

Last Posted Date: 2022-01-18

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 495

Registration Number: NCT02815280

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: FMX-101, 4% minocycline foam
Drug: Vehicle Foam

First Posted Date: 2016-06-28

Last Posted Date: 2022-01-18

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 466

Registration Number: NCT02815267

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea

Phase 2

Completed

Conditions: Papulopustular Rosacea
Rosacea

Interventions: Drug: Vehicle foam (0%)
Drug: FMX-103 1.5%
Drug: FMX-103 3%

First Posted Date: 2015-11-11

Last Posted Date: 2017-02-15

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 233

Registration Number: NCT02601963

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Phase 1

Completed

Conditions: Acne

Interventions: Drug: FMX101, Minocycline 4% foam

First Posted Date: 2014-09-26

Last Posted Date: 2021-02-25

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 12

Registration Number: NCT02250859

Locations: 🇮🇱
Sourasky Medical Center, Clinical Research Center, Tel-Aviv, Israel

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Phase 2

Completed

Conditions: Rash Due to Epidermal Growth Factor Receptor Inhibitors

Interventions: Drug: FDX104 (4% Doxycycline)

First Posted Date: 2014-09-15

Last Posted Date: 2018-02-27

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 24

Registration Number: NCT02239731

Locations: 🇮🇱
Sheba medical center, Tel Hashomer, Israel
🇮🇱
Assaf Harofeh medical center, Rishon LeZion, Israel
🇮🇱
Hadassah Medical Center, Jerusalem, Israel

and more 4 locations

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Phase 2

Completed

Conditions: Prurigo Nodularis

Interventions: Drug: Placebo
Drug: serlopitant

First Posted Date: 2014-07-22

Last Posted Date: 2021-05-20

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 128

Registration Number: NCT02196324

Locations: 🇩🇪
Study Site 07, Berlin-Mitte, Germany
🇩🇪
Study Site 08, Bonn, Germany
🇩🇪
Study Site 12, Dusseldorf, Germany

and more 12 locations

VPD-737 for Treatment of Chronic Pruritus

Phase 2

Completed

Conditions: Chronic Pruritus

Interventions: Drug: VPD-737
Drug: Placebo

First Posted Date: 2013-09-26

Last Posted Date: 2022-05-13

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 257

Registration Number: NCT01951274

Locations: 🇺🇸
Stanford University, Medical Dermatology, Redwood City, California, United States
🇺🇸
Dermatology of Boca, Boca Raton, Florida, United States
🇺🇸
Skin Care Research, Boca Raton, Florida, United States

and more 22 locations

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Topical Minocycline Foam FXFM244

First Posted Date: 2011-05-27

Last Posted Date: 2013-08-15

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 150

Registration Number: NCT01362010

Locations: 🇮🇱
Lev Yasmin clinic, Netanya, Israel
🇮🇱
Tel-Nordau Clalit health services, Tel-Aviv, Israel
🇮🇱
Sourasky medical center, Tel-Aviv, Israel

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Phase 2

Completed

Conditions: Impetigo

Interventions: Drug: Topical Minocycline Foam FXFM244

First Posted Date: 2010-07-28

Last Posted Date: 2013-12-10

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 32

Registration Number: NCT01171326

Locations: 🇮🇱
Lev Yasmin Clinic, Natanya, Israel

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Phase 2

Terminated

Conditions: Rosacea

Interventions: Drug: Topical Minocycline Foam FXFM244

First Posted Date: 2010-06-02

Last Posted Date: 2015-08-26

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 21

Registration Number: NCT01134991

Locations: 🇮🇱
Sourasky Medical Center, Tel-Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy